GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Advanced Medical Solutions Group PLC (LSE:AMS) » Definitions » Cash Conversion Cycle

Advanced Medical Solutions Group (LSE:AMS) Cash Conversion Cycle : 194.66 (As of Dec. 2023)


View and export this data going back to 2002. Start your Free Trial

What is Advanced Medical Solutions Group Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Advanced Medical Solutions Group's Days Sales Outstanding for the six months ended in Dec. 2023 was 65.49.
Advanced Medical Solutions Group's Days Inventory for the six months ended in Dec. 2023 was 216.24.
Advanced Medical Solutions Group's Days Payable for the six months ended in Dec. 2023 was 87.07.
Therefore, Advanced Medical Solutions Group's Cash Conversion Cycle (CCC) for the six months ended in Dec. 2023 was 194.66.


Advanced Medical Solutions Group Cash Conversion Cycle Historical Data

The historical data trend for Advanced Medical Solutions Group's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced Medical Solutions Group Cash Conversion Cycle Chart

Advanced Medical Solutions Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 181.55 200.67 169.15 180.45 222.86

Advanced Medical Solutions Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 142.63 133.24 142.13 168.02 194.66

Competitive Comparison of Advanced Medical Solutions Group's Cash Conversion Cycle

For the Medical Instruments & Supplies subindustry, Advanced Medical Solutions Group's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advanced Medical Solutions Group's Cash Conversion Cycle Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Advanced Medical Solutions Group's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Advanced Medical Solutions Group's Cash Conversion Cycle falls into.



Advanced Medical Solutions Group Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Advanced Medical Solutions Group's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=55.84+208.17-41.15
=222.86

Advanced Medical Solutions Group's Cash Conversion Cycle for the quarter that ended in Dec. 2023 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=65.49+216.24-87.07
=194.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Advanced Medical Solutions Group  (LSE:AMS) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Advanced Medical Solutions Group Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Advanced Medical Solutions Group's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Advanced Medical Solutions Group (LSE:AMS) Business Description

Traded in Other Exchanges
Address
Premier Park, 33 Road One, Winsford Industrial Estate, Winsford, Cheshire, GBR, CW7 3RT
U.K.-based Advanced Medical Solutions was founded in 1991 to design, develop, and manufacture advanced wound-care products for other healthcare manufacturers. AMS' key branded products include the ActivHeal franchise of hydrogel, hydrocolloid, foam, and alginate wound dressings. The firm also manufactures and markets a suite of branded products in surgical use, including the LiquiBand franchise for tissue adhesion and the Resorba line of sutures and collagen-based products for tissue repair. The firm derives approximately 60% of total revenue from branded products, with nonbranded contributing 40%.